Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. lessened its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 11.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,022 shares of the pharmaceutical company's stock after selling 2,227 shares during the period. Envestnet Portfolio Solutions Inc.'s holdings in Vertex Pharmaceuticals were worth $8,253,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of VRTX. Highview Capital Management LLC DE increased its holdings in Vertex Pharmaceuticals by 1.8% in the 4th quarter. Highview Capital Management LLC DE now owns 5,771 shares of the pharmaceutical company's stock valued at $2,324,000 after purchasing an additional 102 shares during the last quarter. Jones Financial Companies Lllp grew its stake in shares of Vertex Pharmaceuticals by 75.5% in the fourth quarter. Jones Financial Companies Lllp now owns 2,468 shares of the pharmaceutical company's stock valued at $994,000 after buying an additional 1,062 shares in the last quarter. Aries Wealth Management purchased a new stake in shares of Vertex Pharmaceuticals in the 1st quarter valued at $293,000. Polar Asset Management Partners Inc. acquired a new position in Vertex Pharmaceuticals during the 4th quarter worth about $22,954,000. Finally, APG Asset Management N.V. boosted its holdings in Vertex Pharmaceuticals by 189.7% during the 4th quarter. APG Asset Management N.V. now owns 359,285 shares of the pharmaceutical company's stock valued at $139,724,000 after acquiring an additional 235,265 shares during the period. Institutional investors and hedge funds own 90.96% of the company's stock.

Vertex Pharmaceuticals Stock Down 1.7%

VRTX stock opened at $440.87 on Friday. The stock has a market cap of $113.22 billion, a P/E ratio of -112.47 and a beta of 0.41. The company has a current ratio of 2.65, a quick ratio of 2.29 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88. The company's 50 day moving average is $459.22 and its two-hundred day moving average is $459.55.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. During the same quarter in the prior year, the business earned $4.76 earnings per share. Vertex Pharmaceuticals's revenue was up 2.6% compared to the same quarter last year. Research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Analysts Set New Price Targets

VRTX has been the topic of a number of recent research reports. Erste Group Bank lowered shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 23rd. Bank of America lifted their price objective on shares of Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a "buy" rating in a report on Monday, March 31st. Leerink Partners reiterated a "market perform" rating and set a $503.00 target price (down from $550.00) on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. JPMorgan Chase & Co. raised their price target on shares of Vertex Pharmaceuticals from $512.00 to $515.00 and gave the company an "overweight" rating in a research report on Tuesday, May 6th. Finally, Wolfe Research lowered Vertex Pharmaceuticals from an "outperform" rating to a "peer perform" rating in a research report on Wednesday, May 7th. Fourteen analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $513.14.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.